Reversal of major genotypic tipranavir mutations under long-term treatment with tipranavir/ritonavir itself with very limited optimized background, during deep salvage antiretroviral therapy. Current HIV research [Curr HIV Res] Journal article | | Title | Reversal of major genotypic tipranavir mutations under long-term treatment with tipranavir/ritonavir itself with very limited optimized background, during deep salvage antiretroviral therapy. | | Author(s) | Sabbatani S, Manfredi R, Fulgaro C, Bon I | | Institution | Department of Clinical and Experimental Medicine, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy. Roberto.manfredi@unibo.it. | | Source | Curr HIV Res 2009 May; 7(3):311-3. | | Abstract | A reversal of key HIV protease mutations against tipranavir has been observed in a patient undergoing a late salvage antiretroviral therapy. Our patient initially introduced tipranavir/ritonavir in absence of an optimized background and novel drug classes, and nevertheless he experienced a virological-immunological benefit. Our report is a contribution to the present debate around the role of each single HIV protease mutation, and the validation of mutational "scores" (like the so-called tipranavir weighted score), to be applied to last-generation protease inhibitor compounds initially targeted on patients with limited, residual therapeutic options. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19442127 |
|
|
| |
Advertise on this site.
| | |
|
